Haemopoietic colony stimulating factors for preterm neonates

Archives of Disease in Childhood: Fetal and Neonatal Edition

Volumn 76, Issue 2, 1997, Pages

  Carr, Robert ^a   Modi, Neena ^b  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 3;

BACTERIAL INFECTION; BACTERICIDAL ACTIVITY; DISEASE ASSOCIATION; HIGH RISK POPULATION; HOST RESISTANCE; HUMAN; INFECTION RISK; MATERNAL HYPERTENSION; MYCOSIS; NEWBORN; NEWBORN INFECTION; PHAGOCYTOSIS; PREMATURITY; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

EID: 0031419220     PISSN: 13592998     EISSN: 14682052     Source Type: Journal    
DOI: 10.1136/fn.76.2.F128     Document Type: Review

References (89)

1. Hensey OJ, Hart CA, Cooke WI. Serious infection in a neonatal intensive care unit: A two-year survey. J Hyg Camb 1985;95:289-97.
2. de Louvois J. Septicaemia and meningitis in the newborn. In: de Louvois J, Harvey D, eds. Infection in the newborn. Chichester: John Wiley & Sons Ltd, 1990:107-15.
3. Baley JE, Fanarorf AA. Neonatal infections. In: Sinclair J, Bracken MB, eds, Effective care of the newborn infant. Oxford: Oxford University Press, 1992:454-506.
4. Freedman RM, Ingram DI, Gross I, Ehrenkranz RA, Warshaw JB, Baltimore RS. A half century of neonatal sepsis at Yale: 1928 to 1978. Am J Dis Child 1981;135:140-4.
5. Gladstone IM, Ehrenkranz RA, Edberg SC, Baltimore RS. A ten-year review of neonatal sepsis and comparison with the previous fifty-year experience. Pediatr Infect Dis J 1990;9:819-25.
6. Gallin JI. Disorders of phagocytic cells. In: Gallin JI, Goldstein IM, Snyderman R, eds. Inflammation: Basic principles and clinical correlates. New York: Raven Press Ltd. 1992:459-74.
7. Manroe BL, Weinberg AG, Rosenfeld CR, Browne R. The neonatal blood count in health and disease.I. Reference values for neutrophilic cells. J Pediatr 1979;95:89-98.
8. Baley JE, Stork EK, Warkentin PI, Shurin SB. Neonatal neutropenia. Clinical manifestations, cause and outcome. Am J Dis Child 1988;142:1161-6.
9. Rodwell RL, Taylor KMCD, Tudehope DI, Gray PH. Hematologie scoring system in early diagnosis of sepsis in neutropenic newborns. Pediatr Infect Dis J 1993;12:372-6.
10. Koenig JM, Christensen RD. Incidence, neutrophil kinetics, and natural history of neonatal neutropenia associated with maternal hypertension. N Engl J Med 1989;321:557-62.
11. Christensen RD. Neutrophil kinetics in the fetus and neonate. Am J Pediatr Hematol Oncol 1989;11:215-23.
12. Cartwright GE, Athens JW, Wintrobe MM. The kinetics of granulopoiesis in normal man. Blood 1964;24:780-803.
13. Christensen RD, MacFarlane JL, Taylor NL, Hill HR, Rothstein G. Blood and marrow neutrophils during experimental group B streptococcal infection: quantification of the stem cell, proliferative, storage and circulating pools. Pediatr Res 1982;16:549-53.
14. Christensen RD, Rothstein G. Pre- and postnatal development of granulocytic stem cells in the rat. Pediatr Res 1984;18:599-602.
15. Christensen RD, Developmental changes in pluripotent hematopoietic progenitors. Early Hum Dev 1988;16:195-205.
16. Erdman SH, Christensen RD, Bradley PP, Rothstein G. Supply and release of storage neutrophils. Biol Neonate 1982;41:132-7.
17. Christensen RD, Harper TE, Rothstein G. Granulocytemacrophage progenitor cells in term and preterm neonates. J Pediatr 1986;109:1047-51.
18. Fauser AA, Messner HA. Proliferative state of human pluripotent hemopoietic progenitors (CFU-GEMM) in normal individuals and under regenerative conditions after bone marrow transplantation. Blood 1979;54:1197-200.
19. Christensen RD, Rothstein G. Exhaustion of mature marrow neutrophils in neonates with sepsis. J Pediatr 1980;96:316-18.
20. Wheeler JG, Chauvenet AR, Johnson CA, Dillard R, Block SM, Boyle R, et al. Neutrophil storage pool depletion in septic, neutropenic neonates. Pediatr Infect Dis 1984;3:407-9.
21. Wilson C. Immunological basis for increased susceptibility of the neonate to infection. J Pediatr 1986;108:1-12.
22. Hill HR. Biochemical, structural, and functional abnormalities of polymorphonuclear leukocytes in the neonate. Pediatr Res 1987;22:375-82.
23. Falconer AE, Carr R, Edwards SW. Impaired neutrophil phagocytosis in preterm neonates: lack of correlation with expression of immunoglobulin or complement receptors. Biol Neonate 1995;68:264-9.
24. Al-Hadithy H, Addison IE, Goldstone AH, Cawley JC, Shaw JC. Defective neutrophil function in low-birth-weight, premature infants. J Clin Pathol 1981;34:366-70.
25. Jaswon MS, Jones MH, Linch DC. The effects of recombinant human granulocyte-macrophage colony stimulating factor on the neutrophil respiratory burst in the term and preterm infant when studied in whole blood. Pediatr Res 1994;36:623-7.
26. Horan TD, English D, McPherson TA. Association of neutrophil chemiluminescence with microbicidal activity. Clin Immunol Immunopathol 1982;22:259-69.
27. Peden DB, Van Dyke K, Ardekani A, Mullett MD, Myerberg DZ, VanDyke C. Diminished chemiluminescent responses of polymorphonuclear leukocytes in severely and moderately preterm neonates. J Pediatr 1987;111:904-6.
28. Driscoll MS, Thomas VL, Ramamurthy RS, Casto DT. Longitudinal evaluation of polymorphonuclear leukocyte chemiluminescence in premature infants. J Pediatr 1990;116:429-34.
29. Barbour AG, Allred CD, Solberg CO, Hill HR. Chemiluminescence production by granulocytes from patients with active bacterial infection. J Infect Dis 1980;141:14-26.
30. Babior BM. The respiratory burst of phagocytes. J Clin Invest 1984;73:599-601.
31. Carr R, Davies JM. Abnormal FcRIII expression by neutrophils from very preterm neonates. Blood 1990;76:607-11.
32. Carr R, Pumford D, Davies JM. Neutrophil chemotaxis and adhesion in preterm babies. Arch Dis Child 1992;67:813-17.
33. Carr R, Huizinga TWJ, Kleijer M, Davies JM. Changes in plasma FcRIII demonstrate increasing receptor production during late pregnancy and after preterm birth. Pediatr Res 1992;32:505-8.
34. Sacchi F, Rondini G, Mingrat G, Stronati M, Gancia GP, Marseglia GL, Siccardi AG. Different maturation of neutrophil chemotaxis in term and preterm newborn infants. J Pediatr 1982;101: 273-4.
35. Eisenfeld L, Krause PJ, Herson V, Savidakis J, Bannon P, Maderazo E, et al. Longitudinal study of neutrophil adherence and motility. J Pediatr 1990;117:926-9.
36. Cannistra SA, Griffin JD. Regulation of the production and function of granulocytes and monocytes. Semin Hematol 1988;25:173-88.
37. Golde DW, Gasson JC. Hormones that stimulate the growth of blood cells. Sci Am 1988;259:34-42.
38. Davis I, Morstyn G. Clinical uses of growth factors. Bailliere's Clin Haematol 1992;5:753-86.
39. Dale DC, Bonilla MA, Davis MW, Nakanishi AM, Hammond WP, Kurtzberg J, et al. A randomized controlled Phase III trial of recombinant human granulocyte colony-stimulating factor (Filgrastim) for treatment of severe chronic neutropenia. Blood 1993;81:2496-502.
40. Moore MAS. The clinical use of colony stimulating factors. Annu Rev Immunol 1991;9:159-91.
41. Nemunaitis J. Granulocyte-macrophage-colony-stimulating factor: a review from preclinical development to clinical application. Transfusion 1993;33:70-83.
42. Sullivan GW, Carper HT, Mandell GL. The effect of three human recombinant hematopoietic growth factors (granulocyte-macrophage colony-stimulating factor, granulocyte colony-stimulating factor, and interleukin-3) on phagocyte oxidative activity. Blood 1993;81:1863-70.
43. Treweeke AT, Aziz KA, Zuzel M. The role of G-CSF in mature neutrophil function is not related to GM-CSF-type cell priming. J Leuk Biol 1994;55:612-16.
44. Cannistra SA, Vellenga E, Groshek P, Rambaldi A, Griffin JD. Human granulocyte-monocyte colony-stimulating factor and interleukin 3 stimulate monocyte cytotoxicity through a tumor necrosis factor-dependent mechanism. Blood 1988;71:672-6.
45. Williams MA, Kelsey SM, Collins PW, Gutteridge CN, Newland AC. Administration of rHuGM-CSF activates monocyte reactive oxygen species secretion and adhesion molecule expression in vivo in patients following high-dose chemotherapy. Br J Haematol 1995;90:31-40.
46. Rapoport AP, Abboud CN, DiPersio JF. Granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF): receptor biology, signal transduction, and neutrophil activation. Blood Rev 1992;6:43-57.
47. Richardson MD, Brownlie CED, Shankland GS. Enhanced phagocytosis and intracellular killing of Candida albicans by GM-CSF-activated human neutrophils. J Med Vet Mycol 1992;30:433-41.
48. Roilides E, Holmes A, Blake C, Venzon D, Pizzo PA, Walsh TJ. Antifungal activity of elutriated human monocytes against aspergillus fumigatus hypae: enhancement by granulocyte-macrophage colony-stimulating factor and Interferon-γ. J Infect Dis 1994;170:894-9.
49. Bodey GP, Anaissie E, Gutterman J, Vadhan-Raj S. Role of granulocyte-macrophage colony-stimulating factor as adjuvant therapy for fungal infection in patients with cancer. Clin Infect Dis 1993;17:705-7.
50. Laver J, Duncan E, Abboud M, Gasparetto C, Sahdev I, Warren D, et al. High levels of granulocyte and granulocyte-macrophage colony-stimulating factors in cord blood of normal full-term neonates. J Pediatr 1990;116:627-32.
51. Bailie KEM, Irvine AE, Bridges JM, McClure BG. Granulocyte and granulocyte-macrophage colony-stimulating factors in cord and maternal serum at delivery. Pediatr Res 1994;35:164-8.
52. Gessler P, Kirchmann N, Kientsch-Engel R, Haas N, Lasch P, Kachel W. Serum concentrations of granulocyte colony-stimulating factor in healthy term and preterm neonates and in those with various diseases including bacterial infections. Blood 1993;82:3177-82.
53. Schibler KR, Liechty KW, White WL, Christensen RD, Production of granulocyte colony-stimulating factor in vitro by monocytes from preterm and term neonates. Blood 1993;82:2478-84.
54. Cairo MS, Yu Suen, Knoppel E, Dana R, Park L, Clark S, et al. Decreased G-CSF and IL-3 production and gene expression from mononuclear cells of newborn infants. Pediatr Res 1992;31:574-8.
55. Cairo MS, Yu Suen, Knoppel E, van de Ven C, Nguyen A, Sender L. Decreased stimulated GM-CSF production and GM-CSF gene expression but normal numbers of GM-CSF receptors in human term newborns compared with adults. Pediatr Res 1991;30:362-7.
56. English BK, Hammond WP, Lewis DB, Brown CB, Wilson CB. Decreased granulocyte-macrophage colony-stimulating factor production by human neonatal blood mononuclear cells and T cells. Pediatr Res 1992;31:211-16.
57. Lee SM, Knoppel E, van de Ven C, Cairo MS. Transcriptional rates of granulocyte-macrophage colony-stimulating factor, granulocyte colony-stimulating factor, interleukin-3, and macrophage colony-stimulating factor genes in activated cord versus adult mononuclear cells: alteration in cytokine expression may be secondary to posttranscriptional instability. Pediatr Res 1993;34:560-4.
58. Cairo MS. Therapeutic implications of dysregulated colony-stimulating factor expression in neonates. Blood 1993;82:2269-72.
59. Liechty KW, Schibler KR, Ohls RK, Perkins SL, Christensen RD. The failure of newborn mice infected with Escherichia coli to accelerate neutrophil production correlates with their failure to increase transcripts for granulocyte colony-stimulating factor and Interleukin-6. Biol Neonate 1993;64:331-40.
60. Cairo MS, van de Ven C, Toy C, Mauss D, Sender L. Recornbinant human granulocyte-macrophage colony-stimulating factor primes neonatal granulocytes for enhanced oxidative metabolism and chemotaxis. Pediatr Res. 1989;26:395-9.
61. Frenck RW Jr, Buescher ES, Vadhan-Raj S. The effects of recombinant human granulocyte-macrophage colony stimulating factor on in vitro cord blood granulocyte function. Pediatr Res 1989;26:43-8.
62. Bedford Russell AR, Davies EG, Gibson FM, Gordon-Smith EC. The in vitro effects of granulocyte and granulocyte-macrophage colony-stimulating factor on interleukin-3-dependent proliferation of human neonatal circulating progenitor cells. Pediatr Res 1995;37:630-3.
63. Westwood NB, Chung R, Emmerson AJB, Pearson TC. The in vitro effects of stem cell factor, interleukin 3 and granulocyte-macrophage colony stimulating factor on haemopoietic progenitor cells from premature infants. Br J Haematol 1994;86:468-74.
64. Cairo MS, van de Ven C, Mauss D, Kommareddy S, Norris K, Sheikh K, Modanlou H. Modulation of neonatal rat myeloid kinetics resulting in peripheral neutrophilia by single pulse administration of Rh granulocyte-macrophage colony-stimulating factor and Rh granulocyte colony-stimulating factor. Biol Neonate 1991;59:13-21.
65. Cairo MS, Plunkett JM, Mauss D, van de Ven C. Seven-day administration of recombinant human granulocyte colony-stimulating factor to newborn rats: modulation of neonatal neutrophilia, myelopoiesis, and group B Streptococcus sepsis. Blood 1990;76:1788-94.
66. Cairo MS, Mauss D, Kommareddy S, Norris K, van de Ven C, Modanlou H. Prophylactic or simultaneous administration of recombinant human granulocyte colony stimulating factor in the treatment of group B streptococcal sepsis in neonatal rats. Pediatr Res 1990;27:612-16.
67. Cairo MS, Mauss D, Plunkett JM, Gillis S, van de Ven C. Modulation of neonatal myelopoiesis in newborn rats after 7 days' administration of either granulocyte-monocyte colony stimulating factor or interleukin-3. Pediatr Res 1991;29:504-9.
68. Frenck RW, Sarman G, Harper TE, Buescher ES. The ability of recombinant murine granulocyte-macrophage colony-stimulating factor to protect neonatal rats from septic death due to staphylococcus aureus. J Infect Dis 1990;162:109-14.
69. Wheeler JG, Givner LB. Therapeutic use of recombinant human granulocyte-macrophage colony-stimulating factor in neonatal rats with type III group B streptococcal sepsis. J Infect Dis 1992;165:938-41.
70. Addison IE, Johnson B, Devereux S, Goldstone AH, Linch DC. Granulocyte-macrophage colony-stimulating factor may inhibit neutrophil migration in vivo. Clin Exp Immunol 1989;76:149-53.
71. Toner GC, Jakubowski AA, Crown JPL, Meisenberg B, Sheridan C, Gabrilove JL. Colony-stimulating factors and neutrophil migration. Ann Intern Med 1989;110:846-7.
72. Roberts RL, Szelc CM, Scates SM, Boyd MT, Soderstrom KM, Davis MW, et al. Neutropenia in an extremely premature infant treated with recombinant human granulocyte colony-stimulating factor. Am J Dis Child 1991;145:808-12.
73. Gillan ER, Christensen RD, Yu Suen, Ellis R, van de Ven C, Cairo MS. A randomized, placebo-controlled trial of recombinant human granulocyte colony-stimulating factor administration in newborn infants with presumed sepsis: significant induction of peripheral and bone marrow neutrophilia. Blood 1994;84:1427-33.
74. Cairo MS, Christensen R, Sender LS, Ellis R, Rosenthal J, van de Ven C, et al. Results of a phase I/II trial of recombinant human granulocyte-macrophage colony-stimulating factor in very low birthweight neonates: significant induction of circulatory neutrophils, monocytes, platelets, and bone marrow neutrophils. Blood 1995;86:2509-15.
75. Bedford Russell AR, Davies EG, Ball SE, Gordon-Smith E. Granulocyte colony stimulating factor treatment for neonatal neutropenia. Arch Dis Child 1995;72:F53-F4.
76. Miller LL, American Society of Clinical Oncology Recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based clinical practice guidelines. J Clin Oncol 1994;12:2471-508.
77. Lieschke GJ, Cebon J, Morstyn G. Characterisation of the clinical effects after the first dose of bacterially synthesised recombinant human granulocyte-macrophage colony-stimulating factor. Blood 1989;74:2634-43.
78. Lieschke GJ, Maher D, O'Connor M, Green M, Sheridan W, Rallings M, et al. Phase I study of intravenously administered bacterially synthesized granulocyte-macrophage colony-stimulating factor and comparison with subcutaneous administration. Cancer Res 1990;50:606-14.
79. Schmitz N, Dreger P, Suttorp M, Rohwedder EB, Haferlach T, Loffler H, et al. Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor). Blood 1995;85:1666-72.
80. Halpérin DS, Wacker P, Lacourt G, Félix M, Babel J-F, Aapro M, et al. Effects of recombinant human erythropoietin in infants with the anemia of prematurity: A pilot study. J Pediatr 1990;116:779-86.
81. Ohls RK, Christensen RD. Recombinant erythropoietin compared with erythrocyte transfusion in treatment of the anaemia of prematurity. J Pediatr 1991;119:781-8.
82. Christensen RD, Liechty KW, Koenig JM, Schibler KR, Ohls RK. Administration of erythropoietin to newborn rats results in diminished neutrophil production. Blood 1991;78:1241-6.
83. Emmerson AJB, Coles HJ, Stern CMM, Pearson TC. Double blind trial of recombinant human erythropoietin in preterm infants. Arch Dis Child 1993;68:291-6.
84. Shannon KM, Mentzner WC, Abels RI, Freeman P, Newton N, Thompson D, et al. Recombinant human erythropoietin in the anaemia of prematurity: Results of a placebo controlled pilot study. J Pediatr 1991;118:949-55.
85. Aglietta M, Monzeglio C, Sanavio F, Aprá F, Morelli S, Stacchini A, et al. In vivo effect of human granulocyte-macrophage colony-stimulating factor on megakaryopoiesis. Blood 1991;77:1191-4.
86. Bonilla MA, Dale D, Zeidler C, Last L, Reiter A, Ruggeiro M, et al. Long-term safety of treatment with recombinant human granulocyte colony-stimulating factor (r-metHuGCSF) in patients with severe congenital neutropenias. Br J Haematol 1994;88:723-30.
87. Fan Dong, Brynes RK, Tidow N, Welte K, Löwenberg B, Touw IP. Mutations in the gene for the granulocyte colony-stimulating-factor receptor in patients with acute myeloid leukemia preceded by severe congenital neutropenia. N Engl J Med 1995;333:487-93.
88. Naparstek E. Granulocyte colony-stimulating factor, congenital neutropenia, and acute myeloid leukemia. N Engl J Med 1995;333:516-18.
89. Rosenthal J, Healey T, Ellis R, Gillan E, Cairo MS. A two-year follow-up of neonates with presumed sepsis treated with recombinant human granulocyte colony-stimulating factor during the first week of life. J Pediatr 1996;128:135-7.